clearly revealed the importance of the O-methyl and vinyl moieties, but did not allow 23 conclusions to be made regarding whether peptide bond cleavage is required for 24
bioactivity (16). 25
The coupling of phosphonic acids to amino acids has been observed in 26 numerous bioactive natural products. In the case of rhizocticin, plumbemycin, bialaphos 27 and phosalacine, these amino acids convert a toxic phosphonate molecule into an 28 inactive "trojan horse" that is readily taken up by target organisms. Once inside the cell, 29 peptidase activity serves to release the bioactive phosphonate moiety (6, 17) . In other 30 cases the entire peptide is required for bioactivity. For example, the angiotensin 31 converting enzyme inhibitor K-26 binds to its target as a tripeptide consisting of Ile-Tyr 32 coupled to (R)-1-amino-2-(4-hydroxyphenyl)-ethylphosphonic acid (AHEP) (2, 23) . 33
Two mutually exclusive mechanisms for dehydrophos bioactivity can be 34 envisioned based on whether the peptide bonds are cleaved or remain intact. In 35 reporting the revised structure of antibiotic, Whitteck et al noted that cleavage of the 36 peptide bond would produce an unstable enamine phosphonate, expected to undergo 37 tautomeric rearrangement followed by spontaneous hydrolysis (Figure 1 on ISP4 plates. Alternatively, filter disks were spotted with 10 µL of an authentic 88 standard dehydrophos (1 mg/mL). These cores and/or disks were then placed onto the 89 freshly inoculated bioassay plates, incubated at 37 °C for 12 hours, and then scored for 90
bioactivity. 91
Overexpression, purification, and activity assay of PepA. PepA was purified 92 using a modified version of the Vogt purification of E. coli aminopeptidase I (27). A 500 93 mL culture of the peptidase A overproducer S. enterica TN2216 was grown for 16 hours 94 at 37 °C and the cells were then harvested by centrifugation at 5000 X g for ten 95
minutes. The cell pellet was resuspended in 20 mL of ice cold buffer 1 (50 mM Tris-HCl 96 pH 7.8, 200 mM KCl, 10 mM MgCl 2 , 100 mM EDTA, 100 mM DTT and 5% glycerol) and 97 disrupted by a single passage through a chilled French press cell at 20,000 psi. Solid 98 debris was removed by centrifugation at 13,000 × g for 30 minutes at 4 °C. The 99 resuspended cells were then placed into a 70 °C water bath and continuously swirled 100 until the temperature reached 65 °C. Precipitated proteins were removed by 101 centrifugation at 13,000 X g for 15 minutes at 4 °C. The supernatant was dialyzed 102 (Pierce 10K MWCO) against 2 L of 0.1M phosphate buffer pH 7.6 for 18 hours at 4 °C 103 with one change of buffer. Following dialysis the extract was centrifuged again at 13,000 104 × g for 15 minutes at 4 °C to remove insoluble material. result also shows that a cytoplasmic target or processing step is required for bioactivity. 136
Dehydrophos action requires peptidase activity. To test whether peptide 137 bond cleavage was required for dehydrophos activity, we examined bioactivity against a 138
series of characterized S. enterica peptidase mutants (22). A quadruple mutant lacking 139
PepA, PepD, PepB and PepN was resistant to dehydrophos, whereas the isogenic 140 strain containing all of the missing peptidases was sensitive to the antibiotic, indicating 141 that dehydrophos action is dependent on peptidase cleavage. Strains carrying any one 142 of the deleted peptidases were also sensitive to dehydrophos; however, the severity of Figure 5 ). Under the conditions used, the reaction proceeded slowly, which allowed for 154 the detection of discrete intermediates. After one hour of incubation, four separate 155 peaks were observed. Based on a spiking experiment with a synthetic standard, the 156 peak with a chemical shift of 10.2 ppm corresponds to unaltered dehydrophos. The 157 peak at 10 ppm is presumed to be dehydrophos lacking the N-terminal glycine 158 (desglycyldehydrophos); however, this could not be rigorously established due to the 159 lack of an appropriate standard. After three hours of incubation, the dehydrophos peak 160 decreased in intensity, while the putative desglycyldehydrophos peak increased. 161
Following overnight incubation, the desglycyldehydrophos peak disappeared and the 162 dehydrophos peak was greatly diminished. Two other peaks were seen in the spectra; 163 one located at 6.2 ppm, and the other at 1 ppm. The peak at 6.2 ppm was transiently 164 observed during the first two time points, but was not observed after the overnight 165 incubation, whereas the peak at 1 ppm increased in intensity over time, and following 166 overnight incubation represented the most abundant phosphorus containing species in 167 the reaction mixture. Spiking of the assay with a synthetic standard identified the 1 ppm 168 peak as MAP. The 6.2 ppm peak was not identified. 169
Dehydrophos bioactivity is not relieved by acetate. Because MAP is a known 170 inhibitor of pyruvate dehydrogenase and pyruvate oxidase, we examined whether the 171 bioactivity of dehydrophos could be relieved by supplementation with acetate, which is 172 Finally, it should be noted that our results suggest that there is significant 227 substrate specificity in both uptake and processing of dehydrophos in S. enterica. These 228 findings are reminiscent of specificity seen in other phosphonate tripeptide antibiotics. 229
For example, rhizocticin and plumbemycin contain the same bioactive component, but 230 differ in the amino acid side chains. Interestingly, rhizocticin is an antifungal compound 231 with little activity towards bacteria, whereas plumbemycin is antibacterial, with little 232 activity towards fungi. It has been proposed that the differences in bioactivity are a 233 reflection of substrate specificity in either uptake or processing (3, 6). This observation 234 has significant implications in the development and design of new, more specific 235 antibiotics. Given the varied nature of oligopeptide uptake and cleavage, an intriguing 236 idea would be the attachment of small molecule inhibitors to multiple peptide scaffolds. 
